Skadden is advising Gilead Sciences, Inc. and its cell therapy subsidiary Kite Pharma, Inc. on their acquisition of Cell Design Labs, Inc. for up to $567 million.
Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates
Skadden is advising Gilead Sciences, Inc. and its cell therapy subsidiary Kite Pharma, Inc. on their acquisition of Cell Design Labs, Inc. for up to $567 million.